Planview Reports Record Q2 and H1 2023, Continues Momentum Amid Challenging Economic Landscape
20.7.2023 18:18:00 EEST | Business Wire | Press release
Planview, the leading platform for digital connected work from portfolio planning to delivery, announced today record annual recurring revenue (ARR) and bookings in Q2, continuing strong momentum and growth in 2023. ACV Bookings for Q2 and the first half of the year were at a record high approaching 30% growth year-over-year (YoY), driven by both new customer additions and customer expansions across financial services, automotive, and healthcare. At the close of H1 2023, Planview is outpacing its forecasts on several key measures, including bookings, retention, and ARR this year. These results are driven by significant demand from customers who require data-driven insights to effectively prioritize initiatives, allocate capital and utilize resources across digital transformation efforts.
“The macroenvironment continues to pose challenges for digital transformation efforts in companies around the world. Organizations are faced with inflation, changing customer expectations, and more conservative budgets,” said Razat Gaurav, CEO at Planview. “At the same time, they must continue to drive forward transformation initiatives to adapt and achieve key business outcomes. Planview’s connected solution is uniquely positioned to give leaders and organizations the data-driven alignment, transparency, and visibility to make critical prioritization decisions, enabling companies to increase productivity, improve time-to-market, and de-risk strategic bets.”
H1 2023 Highlights
- Strong ACV bookings growth for the first half of 2023, approaching 30% growth YoY
- Significant improvements to Retention through first half of 2023, +100bps improvement to Net Retention YoY
- Recurring Revenue grew 13% during the first half of 2023 YoY
- Added over 126 net new customers
- Grew total active users for University of Planview by 29% quarter-over-quarter
Strong New Logo and Customer Momentum
Planview’s outperformance and profitable growth has been driven by new customer wins and expansions. New and notable customers who partnered or significantly expanded their footprint with Planview include AT&T, Axcelis Technologies, Bausch + Lomb, Baylor Scott & White Health, CellCarta, ChristianaCare, Commonwealth Bank of Australia, Corewell Health, Ecopetrol Group, Foodstuffs, Ford Motor Company, Inland Empire Health Plan, LandSure Systems, Mitsubishi UFJ Financial Group, New York Life Insurance Company, Omnicell, OneSavings Bank, PagoNxt, Pladis Global, Schaeffler Group, Schwab, Sherwin-Williams, Sun Life Financial, Transport for NSW, Tronox Holdings, Vanguard Group, Vonage, and Voya.
Industry Leadership & Product Innovation
Key milestones that support continued customer success and the company's strong growth:
- Showcased new Generative AI based assistant at the Reuters Momentum AI Summit.
- Released the landmark 2023 Project to Product State of the Industry Report, which revealed that 40% of Digital Innovation work is being wasted today.
- Recognized for the second consecutive year as a leader in the 2023 Gartner® Magic Quadrant™ for Strategic Portfolio Management. The company was positioned furthest for Completeness of Vision.
- Expanded its global footprint with growing teams in North America, EMEA, Israel and India, with a focus on Artificial Intelligence (AI), Data Science, R&D, Premium Support, Managed Services, InfoSec, and Partners/Strategic Alliances.
- Increased its global partner ecosystem with the additions of UiPath and NTT Data, focused on delivering Value Stream Management capabilities.
- Dramatically expanded its partnership with AWS, including achievement of AWS ISV Accelerate Program membership and the launch of five Planview solutions in the AWS Marketplace.
- Increased in monthly active users by 15% YoY for leading products.
Planview is continuing to invest heavily in product innovation, customer success and go-to-market, building a foundation for continued customer satisfaction and growth in 2023 and beyond.
About Planview
Planview has one mission: to build the future of connected work, from ideas to impact. Planview helps organizations accelerate the achievement of what matters most, supporting our customers from need to speed, from passion to progress, and from overhead to optimization. Our connected platform of solutions underpins the business and digital transformations of more than 4,500 customers globally, including 59 of the Fortune 100. Planview empowers enterprises to improve time-to-market and predictability, increase efficiency to unlock capacity, and ensure their most strategic initiatives deliver the desired business outcomes. Learn more about our portfolio at planview.com, and connect with us on LinkedIn and Twitter.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230720450990/en/
Contact information
Media Relations for Planview
Natalie Reina
Director of Corp Comms
956-878-9176
natalie.reina@planview.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KILL Samsung Bioepis Announces Positive Preliminary Phase 1 Data for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab)6.5.2026 05:14:00 EEST | Press release
Samsung Bioepis Co., Ltd. requests that their press release NewsItemId: 20260505353718 “Samsung Bioepis Announces Positive Preliminary Phase 1 Data for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab)” be killed. The release was issued prematurely by Samsung Bioepis Co., Ltd. The news release will be updated and redistributed in the near future, incorporating further information on SB27.
Samsung Bioepis Announces Positive Preliminary Phase 1 Data for SB27, Proposed Biosimilar to Keytruda (Pembrolizumab)6.5.2026 02:00:00 EEST | Press release
Samsung Bioepis Co., Ltd. announced today that the Phase 1 study on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), has met its primary pharmacokinetics (PK) endpoints. The randomized, double-blind, three-arm, parallel group, multicenter clinical trial demonstrated pharmacokinetic bioequivalence of SB27 (pembrolizumab) to the reference product Keytruda. Initiated in January 2024, Phase 1 study is being conducted in four countries, and is expected to be completed by November 2026.2 The study assessed pharmacokinetics, efficacy, safety, and immunogenicity of SB27, EU-sourced Keytruda, and US-sourced Keytruda in patients with stage II or IIIA non-small cell lung cancer (NSCLC) following complete resection and adjuvant platinum-based chemotherapy. 163 participants were randomized to receive SB27, EU-sourced Keytruda, or US-sourced Keytruda every 3 weeks, maximum 18 cycles over about 51 weeks, and blood samples were collected. The preliminary pharmacokinetic evaluation indicates t
Megaport Launches Built-In DDoS Protection Enabling On-Demand Network Resilience6.5.2026 01:00:00 EEST | Press release
Megaport Limited (ASX: MP1) (“Megaport”), a leading global automated infrastructure platform, today announced the launch of Megaport DDoS Protection. This new, built-in security capability for Megaport Internet allows customers to filter malicious traffic directly within the Megaport network rather than routing it through a separate or external service, for mission-critical uptime without introducing additional latency or routing complexity. As enterprises increasingly migrate to distributed cloud environments, traditional DDoS mitigation has struggled to keep pace with cloud and distributed infrastructure adoption. Standard ISP solutions often resort to dropping all traffic and taking the service offline to protect the network, while external third-party providers force a "security detour" that reroutes traffic through public infrastructure, introducing significant latency and complexity. Megaport DDoS Protection removes these challenges by integrating fabric-native protection directl
IFF Reports First Quarter 2026 Results5.5.2026 23:23:00 EEST | Press release
IFF (NYSE: IFF) reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Consolidated Summary: Management Commentary “IFF is off to a solid start in 2026, with first quarter results that reflect the customer focus and operational execution we’ve been building across the company,” said Erik Fyrwald, CEO of IFF. “We delivered volume growth in all four segments, improved profitability, and generated strong cash flow in the first quarter. As we look ahead, we are maintaining a disciplined approach to how we are planning the balance of the year as the current operating environment remains unsettled. We remained focused on advancing our commercial and innovation pipelines, driving productivity, and working with customers to offset inflation. This – when combined with our solid start to the year – derisks the balance of the year and gives us the confidence to reaffirm our full-year 2026 financial guidance ranges in an uncertain environment. At the same time, w
Logitech Announces Q4 and Full Fiscal Year 2026 Results5.5.2026 23:06:00 EEST | Press release
SIX Swiss Exchange Ad hoc announcement pursuant to Art. 53 LR — Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced financial results for the fourth quarter and full Fiscal Year 2026. For Fiscal Year 2026: Sales were $4.84 billion, up 6 percent in US dollars and 4 percent in constant currency compared to the prior year. GAAP operating income was $775 million, up 18 percent compared to the prior year. Non-GAAP operating income was $911 million, up 18 percent compared to the prior year. GAAP earnings per share was $4.80, up 16 percent compared to the prior year. Non-GAAP EPS was $5.78, up 19 percent compared to the prior year. Cash flow from operations was $1.04 billion. The year-ending cash balance was $1.7 billion. The Company returned $768 million of cash to shareholders through its annual dividend payment and share repurchases. For Q4 Fiscal Year 2026: Sales were $1.09 billion, up 7 percent in US dollars and 3 percent in constant currency compared to Q4 of the prior yea
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom